Prognostic factors in atypical carcinoid tumors

Ahmet Bilgehan Şahin; Erdem Çubukçu; Adem Deligönül; Birol Ocak; Huseyin Melek; Buket Erkan Ozmarasali; Burcu Caner; Ahmet Bayram; Elif Ülker Akyıldız; Türkkan Evrensel

Makale detayları

Prognostic factors in atypical carcinoid tumors

Yazarlar:

Ahmet Bilgehan Şahin | Erdem Çubukçu | Adem Deligönül | Birol Ocak | Huseyin Melek | Buket Erkan Ozmarasali | Burcu Caner | Ahmet Bayram | Elif Ülker Akyıldız | Türkkan Evrensel

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Clinical Oncology | Predictive and Prognostic Markers

Dergi:

The European Research Journal Vol.9 Issue 5, pp.1194-1200

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001288139

pISSN:

2149-3189

Anahtar kelimeler:

Özet:

 Objectives: Carcinoid tumors are rare neuroendocrine neoplasms of the lung. Although typical and atypical carcinoids have different clinical courses, most studies in the literature evaluate them together. Therefore, we aimed to investigate prognostic factors in patients with atypical carcinoids, excluding typical carcinoids. Methods: We included 32 patients with atypical carcinoids according to WHO 2021 criteria admitted to Uludag University Hospital. We retrospectively extracted the clinicopathological characteristics from electronic medical records. The log-rank tests were used to determine the prognostic factors on survival. Results: Median age was 57 24-71 years. Pathological stages were as follows: stage I in 41, II in 9, III in 34, and IV in 16. Median Ki-67 index was 11 1-50. Median follow-up time was 46.2 0.7-184.2 months. 12-month and 48-month disease-free survival DFS rates were 92.3 and 79.2, respectively. 12-month and 48-month overall survival OS rates were 93.8 and 86.2, respectively. Receiver operating characteristic curve analysis determined the Ki-67 cut-off as 12.5. The log-rank test indicated that Ki-67 and stage were statistically significant prognostic factors for DFS and OS. The patients with a Ki-67 index lower than 12.5 had longer DFS and OS  p  0.007 and p  0.020, respectively. Conclusions: The Ki-67 index and 8th TNM staging have prognostic value on DFS and OS in patients with atypical carcinoids. Large-scale studies are needed to define the optimal cut-off value of Ki-67.

 Objectives: Carcinoid tumors are rare neuroendocrine neoplasms of the lung. Although typical and atypical carcinoids have different clinical courses, most studies in the literature evaluate them together. Therefore, we aimed to investigate prognostic factors in patients with atypical carcinoids, excluding typical carcinoids. Methods: We included 32 patients with atypical carcinoids according to WHO 2021 criteria admitted to Uludag University Hospital. We retrospectively extracted the clinicopathological characteristics from electronic medical records. The log-rank tests were used to determine the prognostic factors on survival. Results: Median age was 57 24-71 years. Pathological stages were as follows: stage I in 41, II in 9, III in 34, and IV in 16. Median Ki-67 index was 11 1-50. Median follow-up time was 46.2 0.7-184.2 months. 12-month and 48-month disease-free survival DFS rates were 92.3 and 79.2, respectively. 12-month and 48-month overall survival OS rates were 93.8 and 86.2, respectively. Receiver operating characteristic curve analysis determined the Ki-67 cut-off as 12.5. The log-rank test indicated that Ki-67 and stage were statistically significant prognostic factors for DFS and OS. The patients with a Ki-67 index lower than 12.5 had longer DFS and OS  p  0.007 and p  0.020, respectively. Conclusions: The Ki-67 index and 8th TNM staging have prognostic value on DFS and OS in patients with atypical carcinoids. Large-scale studies are needed to define the optimal cut-off value of Ki-67.

 Objectives: Carcinoid tumors are rare neuroendocrine neoplasms of the lung. Although typical and atypical carcinoids have different clinical courses, most studies in the literature evaluate them together. Therefore, we aimed to investigate prognostic factors in patients with atypical carcinoids, excluding typical carcinoids. Methods: We included 32 patients with atypical carcinoids according to WHO 2021 criteria admitted to Uludag University Hospital. We retrospectively extracted the clinicopathological characteristics from electronic medical records. The log-rank tests were used to determine the prognostic factors on survival. Results: Median age was 57 24-71 years. Pathological stages were as follows: stage I in 41, II in 9, III in 34, and IV in 16. Median Ki-67 index was 11 1-50. Median follow-up time was 46.2 0.7-184.2 months. 12-month and 48-month disease-free survival DFS rates were 92.3 and 79.2, respectively. 12-month and 48-month overall survival OS rates were 93.8 and 86.2, respectively. Receiver operating characteristic curve analysis determined the Ki-67 cut-off as 12.5. The log-rank test indicated that Ki-67 and stage were statistically significant prognostic factors for DFS and OS. The patients with a Ki-67 index lower than 12.5 had longer DFS and OS  p  0.007 and p  0.020, respectively. Conclusions: The Ki-67 index and 8th TNM staging have prognostic value on DFS and OS in patients with atypical carcinoids. Large-scale studies are needed to define the optimal cut-off value of Ki-67.

 Objectives: Carcinoid tumors are rare neuroendocrine neoplasms of the lung. Although typical and atypical carcinoids have different clinical courses, most studies in the literature evaluate them together. Therefore, we aimed to investigate prognostic factors in patients with atypical carcinoids, excluding typical carcinoids. Methods: We included 32 patients with atypical carcinoids according to WHO 2021 criteria admitted to Uludag University Hospital. We retrospectively extracted the clinicopathological characteristics from electronic medical records. The log-rank tests were used to determine the prognostic factors on survival. Results: Median age was 57 24-71 years. Pathological stages were as follows: stage I in 41, II in 9, III in 34, and IV in 16. Median Ki-67 index was 11 1-50. Median follow-up time was 46.2 0.7-184.2 months. 12-month and 48-month disease-free survival DFS rates were 92.3 and 79.2, respectively. 12-month and 48-month overall survival OS rates were 93.8 and 86.2, respectively. Receiver operating characteristic curve analysis determined the Ki-67 cut-off as 12.5. The log-rank test indicated that Ki-67 and stage were statistically significant prognostic factors for DFS and OS. The patients with a Ki-67 index lower than 12.5 had longer DFS and OS  p  0.007 and p  0.020, respectively. Conclusions: The Ki-67 index and 8th TNM staging have prognostic value on DFS and OS in patients with atypical carcinoids. Large-scale studies are needed to define the optimal cut-off value of Ki-67.

Makale detayları

Prognostic factors in atypical carcinoid tumors

Yazarlar:

Ahmet Bilgehan Şahin | Erdem Çubukçu | Adem Deligönül | Birol Ocak | Huseyin Melek | Buket Erkan Ozmarasali | Burcu Caner | Ahmet Bayram | Elif Ülker Akyıldız | Türkkan Evrensel

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Clinical Oncology | Predictive and Prognostic Markers

Dergi:

The European Research Journal Vol.9 Issue 5, pp.1194-1200

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001288139

pISSN:

2149-3189

Lung carcinoid

atypical carcinoid

ki-67 index

stage

survival

Sayı

Makale detayları

Prognostic factors in atypical carcinoid tumors

Yazarlar: Ahmet Bilgehan Şahin | Erdem Çubukçu | Adem Deligönül | Birol Ocak | Huseyin Melek | Buket Erkan Ozmarasali | Burcu Caner | Ahmet Bayram | Elif Ülker Akyıldız | Türkkan Evrensel

Yayıncı: Prusa Medical Publishing

Ana Başlıklar: Clinical Oncology | Predictive and Prognostic Markers

Dergi: The European Research Journal Vol.9 Issue 5, pp.1194-1200

Belge Tipi: Makale

Yayın Tarihi: 4/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001288139

pISSN: 2149-3189

Lung carcinoid

atypical carcinoid

ki-67 index

stage

survival

Sayı

Yazarlar:

Ahmet Bilgehan Şahin | Erdem Çubukçu | Adem Deligönül | Birol Ocak | Huseyin Melek | Buket Erkan Ozmarasali | Burcu Caner | Ahmet Bayram | Elif Ülker Akyıldız | Türkkan Evrensel

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Clinical Oncology | Predictive and Prognostic Markers

Dergi:

The European Research Journal Vol.9 Issue 5, pp.1194-1200

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001288139

pISSN:

2149-3189